Trials / Not Yet Recruiting
Not Yet RecruitingNCT03833206
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- BioLite, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PDC-1421 Capsule | PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient. |
Timeline
- Start date
- 2026-01-15
- Primary completion
- 2027-02-28
- Completion
- 2027-02-28
- First posted
- 2019-02-06
- Last updated
- 2025-02-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03833206. Inclusion in this directory is not an endorsement.